<DOC>
	<DOCNO>NCT00306397</DOCNO>
	<brief_summary>The main purpose study investigate , whether steroid free immunosuppressive treatment valuable alternative treatment de novo kidney transplant recipient possible withdraw calcineurin inhibitor 3 month .</brief_summary>
	<brief_title>Pilot Study Investigate Steroid Free Immunosuppressive Regimen Renal Transplant Recipients</brief_title>
	<detailed_description>Protocol synopsis Title An open , single centre , pilot study investigate steroid free immunosuppressive regimen de novo renal transplant recipient follow two arm randomization calcineurin inhibitor contain calcineurin inhibitor free maintenance immunosuppression three month . Study code Sterfree pilot study Project phase An open , single centre , one arm study follow 1:1 randomize , parallel group , comparative study three month . Study objectives To obtain preliminary information efficacy safety rapamycin / sodium-mycophenolate ( Myfortic ) / tacrolimus regimen absence steroid prevention acute rejection follow renal transplantation . To compare low dose tacrolimus / rapamycin / sodium-mycophenolate ( Myfortic ) regimen rapamycin / sodium-mycophenolate regimen patient without evidence acute rejection three month . Efficacy : Primary endpoint - Plasma creatinine ( creatinine clearance ( Cockcroft ) ) Secondary endpoint - Incidence first acute rejection total number acute rejection - Total number anti-rejection treatment - Patients successfully withdraw calcineurin inhibitor three month - Graft survival - Patient survival Safety : - Graft survival - Patient survival - Protocol biopsies 3 month ( range : day 75 105 ) 6 month ( range day 165 195 ) sub clinical rejection - Incidence first acute biopsy prove rejection total number acute rejection episodes - Total number anti-rejection treatment - Patients switch assigned therapy due rejection side effect - Patients need steroid rejection - Incidence select adverse event : tubulointerstitial nephrotoxicity ( TOR inhibitor ) , leucopenia , thrombocytopenia , elevate fast blood glucose , dyslipidemia , , electrolyte disturbance , de novo insulin dependency , gastrointestinal disorder ( non infectious ) , neurotoxicity . - Patients withdraw due adverse event Long term patient follow Patients follow graft patient survival 12 , 24 , 36 month post-transplantation .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>adult patient end stage kidney disease suitable primary renal transplantation retransplantation patient receive graft living relate , live unrelated braindeath donor patient low high immunological risk constellation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>Steroid free</keyword>
	<keyword>Calcineurin inhibitor free</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sirolimus</keyword>
</DOC>